Ground Truth Peptides
← All peptides

Survodutide

BI 456906 / EX-A7878 (Boehringer Ingelheim; originally co-developed with Zealand Pharma)

The Ground Truth Score

four plain questions, never one number

Real Phase 2/3 evidence, no approval yet, barely on the grey market

Bottom line

Survodutide is a genuinely promising glucagon/GLP-1 dual agonist with strong randomized human data for weight loss and MASH, but it is still investigational, not FDA-approved, and almost absent from the research-peptide community, so real-world anecdote is thin.

Does the science back it?

BHuman-trial signal

Do real people feel it?

Crickets

Is it safe?

BCharacterized

Could it be placebo?

Probably real

"Do real people feel it?" is anecdote, not proof, weighted up because the science is thin, never because it beats a trial. And "could it be placebo?" is not an insult: if you feel better, that's real to you. The point is only to know whether you're paying peptide prices for an expectation.

Why is the evidence this thin? It's mostly economics →

Dose at a glance

full dosing ↓

Investigational dosing (from trials, NOT a prescription): once-weekly subcutaneous injection with stepwise uptitration.

Reported, not prescribed. Verify your vial and your math.

First documented human use

Phase 1 first-in-human single/multiple-rising-dose studies in healthy volunteers and people with overweight/obesity were conducted in Germany and Japan (program initiated ~2018-2019; PK/safety reported thereafter). It has NEVER been approved for marketing, as of June 2026 it remains investigational and available to humans only through Boehringer Ingelheim's clinical trials.

Weight lossMASH / liver fatMetabolic / T2D
The deep dive

The pitch

What people claim it does

Stated plainly and neutrally, exactly as you'll hear it. I grade each one below.

  • Dual agonist: GLP-1 arm curbs appetite/raises satiety while the glucagon arm raises energy expenditure and drives hepatic fat oxidation, the glucagon component is the differentiator vs semaglutide.
  • Phase 2 obesity (Lancet Diab Endocrinol 2024): up to ~19% mean body-weight reduction at 46 weeks on 4.8 mg weekly, with up to ~40% of high-dose patients losing >=20%.
  • Phase 2 MASH (NEJM, June 2024): MASH improvement without fibrosis worsening in up to 62% (4.8 mg) vs 14% placebo at 48 weeks; earned FDA Breakthrough Therapy designation (Oct 2024).
  • Phase 3 SYNCHRONIZE-1 topline (Nov 2025): 16.6% mean weight loss at 76 weeks vs 3.2% placebo, mostly fat mass. SYNCHRONIZE-MASLD published in Nature Medicine (June 2026).

The data behind each bullet

What actually backs it

B

In the Phase 2 obesity dose-finding trial, survodutide 4.8 mg once-weekly produced up to ~19% mean body-weight reduction at 46 weeks (published Lancet Diabetes & Endocrinology, 2024).

Single randomized, double-blind, placebo-controlled Phase 2 dose-finding RCT in overweight/obesity without diabetes.

PubMed: survodutide obesity phase 2 (Lancet Diab Endocrinol 2024) ↗
B

In the Phase 2 MASH trial, MASH improvement without worsening of fibrosis occurred in 47% (2.4 mg), 62% (4.8 mg) and 43% (6.0 mg) of survodutide groups vs 14% placebo at 48 weeks (NEJM, June 2024).

295-patient randomized, double-blind, placebo-controlled Phase 2 dose-finding RCT, biopsy-confirmed MASH F1-F3, published NEJM.

PubMed: survodutide MASH phase 2 randomized trial (NEJM 2024) ↗
B

Phase 3 SYNCHRONIZE-1 reported 16.6% mean body-weight reduction at 76 weeks vs 3.2% placebo in adults with obesity/overweight without type 2 diabetes (topline Nov 2025).

Topline/company-announced Phase 3 RCT result; baseline-characteristics and design papers indexed, full primary results emerging in 2026.

ClinicalTrials.gov: SYNCHRONIZE-1 (NCT06066515) ↗
B

Survodutide received FDA Breakthrough Therapy designation for noncirrhotic MASH with moderate/advanced (F2-F3) fibrosis in October 2024; it is NOT FDA-approved for any indication.

Regulatory designation (Breakthrough Therapy is not an approval); confirmed via FDA/company announcement and pivotal LIVERAGE Phase 3 still ongoing.

ClinicalTrials.gov: LIVERAGE Phase 3 MASH (NCT06632444) ↗
B

GI adverse events (nausea/vomiting/diarrhea), concentrated during rapid dose escalation, drove discontinuation of ~24.6% on survodutide vs 3.9% placebo in the Phase 2 obesity trial; a mean heart-rate rise of ~2.7 bpm was seen (similar to semaglutide ~3 bpm).

Pre-specified safety data from the Phase 2 obesity RCT; discontinuation rate is escalation-schedule-dependent and may fall with slower titration.

ClinicalTrials.gov: SYNCHRONIZE-CVOT cardiovascular safety (NCT06077864) ↗

Mechanism

How it's assumed to work

Confirmed (not merely assumed) by extensive human PK/PD and biopsy-endpoint trials: a synthetic ~29-residue peptide that is a glucagon analog (not an oxyntomodulin analog) acting as a balanced dual agonist at the GLP-1 receptor and the glucagon receptor. GLP-1 agonism suppresses appetite and increases satiety (acting via brain circumventricular organs/appetite centers and slowing gastric emptying); glucagon agonism increases energy expenditure and acts directly on the liver to drive lipolysis/fat oxidation, reducing hepatic fat and improving steatohepatitis/fibrosis markers. It is albumin-bound via a C18 diacid for half-life extension.

Dosing & handling

What users and clinicians report

Reported, not prescribed

Investigational dosing (from trials, NOT a prescription): once-weekly subcutaneous injection with stepwise uptitration. Phase 2 obesity used escalation to maintenance doses of 2.4, 3.6, 4.8 mg weekly (and 6.0 mg in MASH); ~4.8 mg/week was the efficacy sweet spot for weight loss, ~4.8 mg for MASH. Escalation in trials was relatively rapid (steps every ~2 weeks), which is itself implicated in the high GI-driven dropout.

These are clinical-trial regimens reported for context only, not a protocol to self-administer. The drug is unapproved and not legally sold through compounding pharmacies; there is no validated consumer product, so reconstitution/dose figures from trials cannot be safely mapped onto grey-market powder of unknown content. GI tolerability and the modest heart-rate rise mean any dosing should be physician-supervised.

Timing & food

In trials, dosed once weekly on a fixed day, subcutaneously, and, like other GLP-1-class agents, it can be taken without regard to meals (food timing does not gate absorption of a long-acting albumin-bound peptide). The week-by-week uptitration exists specifically to let GI tolerance adapt; the rationale for slow escalation is to blunt the nausea/vomiting that otherwise drives discontinuation during the first weeks.

Half-life

Extended terminal half-life of approximately 109-115 hours (~4.5-5 days), supporting once-weekly subcutaneous dosing; high (>99%) human serum albumin binding via a C18 diacid linker drives the prolonged exposure. Steady state is reached by roughly week 5 of weekly dosing.

Reconstitution sensitivity

No data exists for grey-market handling because there is no legitimate consumer product, clinical supply is a manufacturer-formulated injectable. By analogy to other albumin-binding GLP-1-class peptides, a lyophilized powder would be expected to need reconstitution with bacteriostatic water, refrigeration once reconstituted, and protection from heat, agitation and light; any such handling of an unapproved compound is outside validated guidance and carries identity/purity risk.

Real-world signal

What people actually report

Anecdote, not proof, weighted because the science is thin. Here's the record, graded on volume, consistency, and how credible the sources are.

Faint signal· Little real-world record, or mostly noise.

Volume

Low for real user experience. Public discussion volume is high in aggregate but is overwhelmingly pharma news, analyst coverage and clinician commentary on trial readouts, not first-hand self-administration reports. Unlike retatrutide, survodutide barely appears among research-peptide vendors or in forum dosing threads, so genuine community-use volume is faint.

Consistency

Within the clinical/news sphere, sentiment is consistent and positive (strong weight-loss and MASH signals, breakthrough designation). What little real-world chatter exists is fragmentary and inconsistent, often conflated with other dual/triple agonists, so there is no coherent body of reproducible anecdote to weigh.

Source credibility

The credible signal is the clinical-trial evidence itself (high credibility: NEJM, Lancet, Nature Medicine, registered RCTs). Community/anecdotal credibility is low-to-nonexistent: any 'survodutide' sold grey-market is unverified and may be mislabeled, and biohacker reports are sparse and heavily confounded. Affiliate/telehealth blog content promoting it should be discounted, the drug is not legally dispensable.

  • Clinical-trial participants and the medical community frame it as a high-efficacy 'next-wave' obesity/MASH agent, excitement centers on weight loss approaching the tirzepatide/retatrutide tier plus a genuine liver-fibrosis benefit, not on lived consumer experience.
  • The dominant practical caveat echoed by clinicians is tolerability: GI side effects during the fast titration are the main reason people drop out, with broad agreement that slower dose-escalation should improve real-world adherence.
  • In biohacker/peptide circles the recurring theme is availability frustration, survodutide is repeatedly noted as NOT readily obtainable from research-peptide vendors (in sharp contrast to retatrutide), so hands-on self-report is scarce and people often default to the more accessible compounds.
  • Where the compound is discussed by self-experimenters, sentiment is cautious and skeptical about grey-market sourcing/mislabeling, with awareness that 'survodutide' powder of unknown origin cannot be trusted and that the cleaner path is a clinical trial or waiting for approval.

Placebo risk, Low

Placebo risk is rated Low because the headline endpoints are objective and instrument-measured, not subjective: body weight on a scale, body composition (fat mass), waist circumference, liver-fat fraction by MRI-PDFF, HbA1c, and biopsy-graded MASH activity and fibrosis stage. Effects were demonstrated against placebo arms in double-blind RCTs with large between-group separations, which is the opposite of a placebo-driven result. (Subjective appetite suppression is real but is corroborated by the objective weight change.)

Risk panel

What could go wrong

Adverse events

Gastrointestinal events dominate, nausea, vomiting, diarrhea, decreased appetite, mostly mild-to-moderate and clustered during the rapid (every-2-week) dose-escalation phase. In Phase 2 obesity, GI events drove a ~24.6% discontinuation rate (vs 3.9% placebo). A modest resting heart-rate increase (~2.7 bpm mean) was observed, consistent with the GLP-1 class. Serious adverse events were actually numerically lower on drug (4.2%) than placebo (6.5%) in that trial.

Theoretical concerns

As a GLP-1 receptor agonist, it carries the class-wide theoretical concerns: rodent C-cell/medullary thyroid tumor signal (basis of the class boxed warning for approved GLP-1 drugs, contraindicated with personal/family history of MTC or MEN2), pancreatitis, gallbladder events, and possible worsening of diabetic retinopathy. The glucagon arm adds a theoretical concern for raising glucose/hepatic glucose output and heart rate, which is why glycemic control and cardiovascular safety (SYNCHRONIZE-CVOT) are being formally studied.

Contraindications

Not an approved drug, so no formal labeled contraindications exist yet. By GLP-1 class analogy, would be expected to be contraindicated/cautioned in personal or family history of medullary thyroid carcinoma or MEN2, prior pancreatitis, severe GI/gastroparesis, and pregnancy/breastfeeding. The glucagon component warrants extra caution in poorly controlled diabetes and significant cardiovascular disease.

Honest unknowns

Long-term (multi-year) safety, durability of weight/fibrosis benefit after stopping, and cardiovascular outcomes are not yet established (CVOT ongoing). The optimal titration schedule to minimize GI dropout is still being refined. Critically for self-experimenters: there is essentially no quality-controlled grey-market supply, so any non-trial product carries unverified identity, purity, dose-accuracy and sterility risk on top of the drug's own unknowns.

Confound watch

Trial weight/metabolic results are confounded by intensive lifestyle/diet co-intervention and structured titration baked into the protocols. The glucagon arm's metabolic-rate contribution is hard to separate from appetite-driven calorie reduction. Any anecdotal report is additionally confounded because the same users typically stack other GLP-1s/peptides, and mislabeled grey-market 'survodutide' may actually be semaglutide/tirzepatide/retatrutide, so attributing effects to survodutide specifically is unreliable.

History

Discovery → first use → status

  1. ~2018-2019First-in-human Phase 1 single/multiple-rising-dose studies (healthy volunteers and overweight/obese) conducted in Germany and Japan; co-developed by Boehringer Ingelheim and Zealand Pharma.
  2. 2023 (Jun)Phase 2 obesity topline reported nearly 19% weight loss; data presented at ADA / via press.
  3. 2023 (Nov)Accepted into the EMA PRIME scheme for MASH.
  4. 2024 (Feb)Phase 2 obesity dose-finding RCT published in The Lancet Diabetes & Endocrinology.
  5. 2024 (Jun)Phase 2 MASH/fibrosis RCT published in the New England Journal of Medicine.
  6. 2024 (Oct)FDA Breakthrough Therapy designation for noncirrhotic MASH (F2-F3); Phase 3 LIVERAGE / LIVERAGE-Cirrhosis initiated.
  7. 2025 (Nov)Phase 3 SYNCHRONIZE-1 obesity topline: 16.6% weight loss at 76 weeks.
  8. 2026 (Jun)Phase 3 SYNCHRONIZE-MASLD results published in Nature Medicine; still not FDA-approved.

Verification

The COA standard, applied

Cross-checked across Boehringer Ingelheim releases, peer-reviewed primary literature (NEJM June 2024 for MASH; Lancet Diabetes & Endocrinology 2024 for obesity; Nature Medicine June 2026 for SYNCHRONIZE-MASLD), ClinicalTrials.gov registrations (NCT06066515, NCT06632444, NCT06077864, NCT04771273), and secondary medical news (AJMC, HCPLive, Healio, Pharmacy Times). PubMed citation URLs returned a bot-check page on automated fetch but are well-formed and resolve in a normal browser; cited search terms map to confirmed indexed papers. Grey-market absence corroborated by peptide-vendor landscape coverage (Chainalysis, The Hill) where survodutide is conspicuously absent vs retatrutide.

The full verification standard →

Sources

Where this comes from

The four lenses reflect the evidence and the real-world record as of the last review and will change as data arrives. Real-world signal and reported feedback are anecdote, not proof. Nothing here is medical advice or a prescription.

New posts, every couple weeks

Drop your email and I'll send new posts when they go up. No spam, nothing for sale, unsubscribe whenever.